A venture capital firm with offices throughout North America and Europe has raised 6 funds to date and currently has over $2.3 billion AUM. The firm predominantly focuses on seed and series A and B investments in early stage biotechnology companies, as well as growth equity investments in medical devices companies. The firm’s typical investment size for early stage companies is $5M-$15M and the firm can allocate up to $35-40M total over the life of an investment. The firm focuses on companies that are based in the U.S., Canada and Europe and is actively seeking new investment opportunities.

The firm closed its new fund in early 2017 and the firm will use its diversified global investment strategy to find, form and fund innovative healthcare companies with an emphasis on novel therapeutics. This fund was highly oversubscribed and was supported by existing and new limited partners, and will invest in 20‐25 biotechnology companies in the U.S., Canada and Europe.

The firm is opportunistic in terms of subsectors and indications. The firm is interested in novel small molecule and biologic therapeutics that address immuno-oncology, orphan/rare or genetic-based diseases, inflammation, infectious diseases and specific viruses, microbiome, and fibrosis and CNS indications. The firm is also interested in regenerative medicine and gene therapy. In medical devices, the firm is generally agnostic to subsector, but is more interested in revenue-generating devices that address cardiovascular, orthopedic, ophthalmic and neurological disorders. The firm prefers devices with proof-of-concept and strong IP.

The firm seeks a company with a strong and experienced management team or technical experts in the relevant technology. The firm generally is flexible with management teams.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com.

A London-based firm invests in venture to expansion stage life sciences companies, investing from Series B rounds and on. The firm looks to invest in companies that are in clinical trials or are close to/just received approval by the FDA (or CE mark in Europe), but will consider pre-clinical companies in rare cases, when the technology is a good fit and opens up a new therapeutic domain. Initial investments are typically $8-10 million, with the possibility of follow-on investments. Half of the firm’s investments are in Europe and half are in the US.

The firm’s primary investment theme is in medical devices, but is only interested in devices that are highly disruptive in existing markets or which represent completely new markets. The firm will consider any indication but is particularly interested in products providing a more efficient solution for the healthcare system (minimally invasive, improved health economics) that are relevant to the aging population. Indications of interest include cardiovascular applications, neuromodulation, neurostimulation, respiratory and orthopedics. The firm will also consider diagnostics companies.

The firm prefers to invest in companies with strong management teams led by serial entrepreneurs. The firm likes to be an active investor, taking a board seat for their portfolio companies, often leading funding rounds. They are also often helping to recruit experts to the board or to management positions in the company via their extensive network in the medtech space.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com.

A pharmaceutical arm of a Japanese conglomerate consists of multiple business operations, including a US licensing and clinical development office, as well as a Japan-based sales division. The firm is seeking to form partnerships and in-licensing relationships regarding early stage assets in its key indication areas. These partnerships are highly flexible, and may involve the firm contributing personnel, sharing studies and research tools, or providing research expense funding.

The firm is interested in early-stage, first-in-class, orally active small molecule NCEs. The firm seeks assets in the following key areas: metabolic disease (type 2 diabetes and its complications, dyslipidemia, NASH, and energy metabolism in Alzheimer’s disease), infectious disease (functional cures for HIV and Hepatitis B), cardiovascular disease (CHF, peripheral arterial disease and pulmonary arterial hypertension), autoimmune disease (multiple sclerosis, lupus, IBD, systemic scleroderma, and organ fibrosis). Additionally, the firm is interested in sarcopenia & cachexia, chronic kidney disease, pain (peripheral targets), and osteoporosis (osteogenesis only). As well as drugs, the firm is interested in drug targets in these disease areas. The firm is open to forming partnerships regarding very early stage assets, at or prior to the lead optimization phase.

For in-licensing for the Japan market, the firm is focused on renal diseases, dermatology and allergic diseases.

The firm also invests in drug discovery technologies and research tools such as: technologies related to translational research using cell culture, isolated cellular organelles and related mechanisms; HTS technologies; protein structure analysis; chemical biology, chemical synthesis, and chemical libraries; biophysical tools; in silico technologies; biomarkers and bioinformatics screening, biomarker research, and compound libraries.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com.

A service provider and investor headquartered in Madrid, Spain is starting a fund to support research and development in Europe. The firm is looking to fund companies, whether headquartered in the US or in Europe, doing research or clinical trials in Europe. The firm’s model is similar to a non-dilutive grant: the fund will pay €600K-800K of every €1M in research or clinical trial funding needed. The firm will fund deals involving research spanning 2-3 years with at least €.5M committed a year, but prefers bigger investment sizes with ~€10M in research funding with €6-8M provided by the firm.

The firm is interested in companies in therapeutics, medical devices or diagnostics looking to do research or hold clinical trials in Europe. The firm is agnostic to subsector and indication.

The firm’s only requirement is that the company conduct its research or clinical trial in Europe.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com.